Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). CLL ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
© 2026 Forbes Media LLC. All Rights Reserved.
© 2026 Forbes Media LLC. All Rights Reserved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results